Prescription Drug User Fee Act

Prescription Drug User Fee Act is a pivotal United States law that fundamentally altered the funding and operations of the Food and Drug Administration (FDA). Enacted in 1992, it authorized the agency to collect fees from pharmaceutical manufacturers to expedite the review process for new drug applications. This legislation was a direct response to criticism over lengthy approval times and has been reauthorized every five years, significantly shaping the modern drug development landscape in the United States.

Background and legislative history

By the late 1980s, the Food and Drug Administration faced intense scrutiny from Congress, patient advocacy groups like the AIDS Coalition to Unleash Power, and the pharmaceutical industry over perceived delays in reviewing new medications. The HIV/AIDS crisis highlighted these bottlenecks, as promising therapies remained unavailable. Key legislators, including Henry Waxman and John Dingell, spearheaded hearings through the United States House Committee on Energy and Commerce. The model for the act was influenced by a similar fee system used by the United Kingdom's regulatory agency. With bipartisan support, the legislation was passed by the 102nd United States Congress and signed into law by President George H. W. Bush in October 1992.

Key provisions and fee structure

The act established a framework where sponsors must pay fees to the Food and Drug Administration upon submission of a New Drug Application or a Biologics License Application. These fees are categorized into application fees, establishment fees for manufacturing facilities, and product fees for each approved drug. The revenue is dedicated solely to enhancing the resources of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. Fee amounts and revenue targets are negotiated between the FDA, Pharmaceutical Research and Manufacturers of America, and Congress during each reauthorization cycle, with provisions to waive fees for small businesses or orphan drugs under the Orphan Drug Act.

Impact on FDA review times and drug approval

The infusion of user fee revenue allowed the Food and Drug Administration to hire hundreds of additional reviewers, statisticians, and project managers. This directly contributed to a dramatic reduction in median review times for standard applications, from over 30 months prior to 1992 to under 12 months by the late 1990s. The act also enabled the implementation of performance goals and review deadlines, creating a more predictable regulatory pathway. Landmark approvals facilitated under this system include numerous therapies for cancer, cardiovascular disease, and hepatitis C. The success of this model led to analogous acts for medical devices, the Medical Device User Fee and Modernization Act, and animal drugs.

Controversies and criticisms

Critics, including the Public Citizen Health Research Group and some members of Congress, have argued that the act creates a problematic dependency of the Food and Drug Administration on the industry it regulates, potentially compromising regulatory independence. Concerns about "regulatory capture" were highlighted during controversies surrounding the approval and subsequent safety issues of drugs like Vioxx. Some patient advocates contend that the focus on speed has sometimes come at the expense of robust post-market safety surveillance. Debates also persist over whether the fee structure disadvantages smaller biotechnology companies and academic researchers.

Reauthorizations and amendments

The act requires reauthorization every five years, with each iteration, known as PDUFA II through PDUFA VII, incorporating new mandates. Major amendments have expanded the scope of fees to include direct-to-consumer advertising review and established programs for drug safety under the Food and Drug Administration Amendments Act of 2007. Later reauthorizations, negotiated during the administrations of Presidents Barack Obama, Donald Trump, and Joe Biden, have integrated provisions from the 21st Century Cures Act, emphasizing patient experience data, rare disease therapies, and advanced manufacturing technologies. These continuing negotiations ensure the act remains a cornerstone of FDA funding and modern therapeutic development.

Category:United States federal healthcare legislation Category:Food and Drug Administration Category:1992 in law